Recent studies revealed new molecular pathways by which IGF-2 confers androgen independent growth or can ignite the de novo steroidogenesis engine and promote molecular events associated with tumour progression evading hormone therapy (Lubik et al. 2013; Comstock and Knudsen 2013). The gene discussed is IGF2; the disease is neoplasm.